Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | GSK3B | P49841 | 2/20 | 0.32 |
| ▸ | GCGR | P47871 | 1/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Carbamic Acid SCHEMBL4573817 | 0.94 | CDC7 (0.33) | CYP3A4GSK3B | |
| SCHEMBL7086339 | 0.90 | TSHR (0.30) | GCGR | |
| SCHEMBL7079911 | 0.90 | SLC2A1 (0.34) | — | |
| SCHEMBL6966853 | 0.90 | TDP1 (0.33) | — | |
| SCHEMBL6972838 | 0.88 | ADRB2 (0.34) | — | |
| SCHEMBL7083004 | 0.88 | GSK3B (0.32) | CYP1A2CYP3A4CYP2C9CYP2C19GSK3B | |
| SCHEMBL6973659 | 0.87 | MEN1 (0.34) | CYP3A4KCNH2 | |
| SCHEMBL6960986 | 0.87 | GSK3B (0.32) | CYP1A2CYP3A4CYP2C9CYP2C19GSK3B | |
| SCHEMBL7078351 | 0.85 | SLC6A4 (0.36) | CYP1A2CYP3A4CYP2C9CYP2C19GSK3B | |
| SCHEMBL597335 | 0.85 | MEN1 (0.31) | CYP3A4GSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250091995-A1 | STABLE CRYSTAL OF 4-OXOQUINOLINE COMPOUND | JAPAN TOBACCO INC. (JP) | 2025-03-20 | — | — | US | disclosed |
| EP-2793904-A1 | INHIBITORS OF SIALOADHESIN FOR THE TREATMENT OF DISEASES CAUSED BY ENVELOPED VIRUSES | Laboratorios Del. Dr. Esteve, S.A. (ES) | 2014-10-29 | — | — | EP | disclosed |
| WO-2013092509-A1 | INHIBITORS OF SIALOADHESIN FOR THE TREATMENT OF DISEASES CAUSED BY ENVELOPED VIRUSES | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2013-06-27 | — | — | WO | disclosed |
| EP-0786455-B1 | IMIDAZOLE DERIVATIVE | SHIONOGI & CO (JP) | 2003-12-03 | — | — | EP | disclosed |
| US-6147097-A | METHOD FOR TREATING AIDS | SHIONOGI & CO., LTD. (JP) | 2000-11-14 | — | — | US | disclosed |
| US-5910506-A | IMIDAZOLE DERIVATIVES, E.G.5-(3,5-DICHLOROPHENYLTHIO)-1,2-DIMETHYL-4-ISOPROPYL-1H-IMIDAZOLE; VIRICIDES; AIDS; NONTOXIC | SHIONOGI & CO., LTD. (JP) | 1999-06-08 | — | — | US | disclosed |
| EP-0786455-A1 | IMIDAZOLE DERIVATIVE | SHIONOGI & CO., LTD. (JP) | 1997-07-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250091995-A1 | STABLE CRYSTAL OF 4-OXOQUINOLINE COMPOUND | KCNQ2, KCNQ1, KCNQ5 | CYP1A2 40/4885CYP3A4 31/4885CYP2C9 195/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.